Victoire Cardot‐Ruffino

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Cindy Neuzillet · 5 shared papers, 2019–2026 · strength 0.78
   • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
   • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
   • Paper Pancreatic cancer orthotopic graft in a murine model. DOI 10.1590/acb382823↗
2. Stephanie K. Dougan · 5 shared papers, 2023–2026 · strength 0.77
   • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
3. Lestat R. Ali · 4 shared papers, 2023–2026 · strength 0.63
   • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
4. Brian Matthew Wolpin · 4 shared papers, 2023–2026 · strength 0.63
   • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
5. Jonathan Andrew Nowak · 4 shared papers, 2023–2026 · strength 0.63
   • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
6. Michael Lawrence Dougan · 3 shared papers, 2023–2026 · strength 0.47
   • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
   • Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
   • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
7. Matthieu Delaye · 2 shared papers, 2023–2026 · strength 0.44
   • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
   • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
8. Marc Hilmi · 2 shared papers, 2023–2026 · strength 0.44
   • Paper Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: th… DOI 10.1016/j.dld.2026.10.006↗
   • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
9. Andressa Dias Costa · 3 shared papers, 2023–2024 · strength 0.44
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
   • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
10. Osama E. Rahma · 3 shared papers, 2023–2024 · strength 0.44
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
11. Milena Muzzolini · 2 shared papers, 2023 · strength 0.39
    • Paper The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. DOI 10.1016/s2468-1253(23)00207-8↗
    • Paper Pancreatic cancer orthotopic graft in a murine model. DOI 10.1590/acb382823↗
12. Thomas E. Clancy · 2 shared papers, 2024–2026 · strength 0.35
    • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
13. Joseph Douglas Mancias · 2 shared papers, 2024–2026 · strength 0.35
    • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
14. Harshabad Singh · 2 shared papers, 2024–2026 · strength 0.33
    • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
15. Douglas Adam Rubinson · 2 shared papers, 2024–2026 · strength 0.33
    • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
16. Brandon M. Huffman · 2 shared papers, 2024–2026 · strength 0.33
    • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
17. Kimberly J. Perez · 2 shared papers, 2024–2026 · strength 0.33
    • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
18. James M. Cleary · 2 shared papers, 2024–2026 · strength 0.33
    • Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
19. Craig Lee Slingluff · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
20. Matthew H. G. Katz · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
21. Chee‐Chee Stucky · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
22. Rawad Elias · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
23. Matthew J. Reilley · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
24. Nipun B. Merchant · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
25. Todd W. Bauer · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.